S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS

R. Andrew Shippy, Douglas Mendez, Kristina Jones, Irene Cergnul, Stephen E. Karpiak

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Background: This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management of depression in a population reluctant to add another "pill" or another set of related side effects to an already complex highly active antiretroviral therapy (HAART) regimen. Methods: The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after initiation of treatment with SAM-e. Results: Data show a significant acute reduction in depressive symptomatology, as measured by both the HAM-D and the BDI instruments. Conclusions: SAM-e has a rapid effect evident as soon as week 1 (p < .001), with progressive decreases in depression symptom rating scores throughout the 8 week study.

Original languageEnglish (US)
Article number38
JournalBMC Psychiatry
Volume4
DOIs
StatePublished - Nov 11 2004

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS'. Together they form a unique fingerprint.

Cite this